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ations of endothelial cells [2].
Normally the vascular endothelium not only provides an antithrom-
botic and anticoagulant balance but also tonic vasodilation that controls
blood ﬂow and pressure. Once this athero-protective phenotype is
transformed, endothelial cells become an active beacon for the activa-
tion of immune responsive cells such as monocytes, macrophages, TAtherogenesis
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Inﬂammatory markersCardiovascular disease is the leading global cause of death, account-
ing for 17.3 million deaths per year, a number that is expected to grow
to N23.6 million by 2030 [1]. In 2008, CVD deaths represented 30% of all
global deaths [2].
The pathogenesis of atherosclerosis has undergone a critical revolu-
tion over the last three decades. The traditional view that atherosclero-
sis was mainly characterized by accumulation of cholesterol within the
arterial wall leading to ﬂow limiting stenoses eventually resulting in
signs and symptoms of ischemia due to impaired perfusion has evolved
considerably to incorporate new molecular and cellular pathways of
chronic inﬂammation in promoting atherothrombosis [2].
Three decades ago, besides age, cholesterol and LDL concentrations
were seen as invaluable risk markers for future cardiovascular events.
Despite this important role of cholesterol in atherosclerosis, it became
clear that many individuals who experienced a myocardial infarction
have cholesterol concentrations at or below the National Cholesterol
Education Program thresholds of 200 mg/dL for total cholesterol and
130 mg/dL for LDL cholesterol [3].
Currently, both dyslipidemia and inﬂammation are seen as partners
in this vicious cycle triggering atheroma formation and proliferation.
Basically, atherosclerosis is likely to start with an innate immune
response involving the recruitment and activation ofmonocytesmacro-
phages that respond to an excessive accumulation of modiﬁed lipids
within the arterial wall, followed by an adaptive immune response
involving antigen-speciﬁc T lymphocytes [2].
Even though the entire vascular endothelium is susceptible to vascu-
lar injury, the initial atherosclerotic plaque tends to occur at speciﬁc
sites characterized by signiﬁcant alterations in arterial ﬂow of many
middle and large arteries, especially at bifurcation sites. Speciﬁcally, aten access article under the CC BY-NCthese sites regional areas of ﬂow disturbance induce mechanical alter-
lymphocytes, neutrophils, and mast cells as well as by resident smooth
muscle and dendritic cells to form the atheromatous plaque [2].
Particularly important in this cascade of events is the action of acti-
vated T cells that enter lesions in response to the chemokine-inducible
protein-10, monokine induced by interferon-γ, and interferon-
inducible T cell α-chemoattractant [2]. The atherosclerotic lesion also
contains cytokines that promote a T-helper 1 response known to ampli-
fy the local inﬂammatory activity by producing proinﬂammatory
cytokines such as interferon-γ and CD40 ligands 40 L and 154, which
contribute importantly to plaque progression [2]. Furthermore,
adiponectin, a product of adipose tissue, having insulin-sensitizing,
antiatherogenic, and antiinﬂammatory properties is also increased in
the atherogenic plaque [2].
Macrophages also play important roles in the progression of
atherosclerosis by exhibiting unique characteristics under the various
stimuli, evolving the plaque instability, thrombus formation and remod-
eling [2].
Translating all this basic data into useful clinical information,
results from multiple large-scale prospective studies have shown that
C-reactive protein (CRP) strongly and independently predicts adverse
cardiovascular events, including myocardial infarction, ischemic stroke,
and sudden cardiac death [4,5]. Concentrations of high sensitive
CRP (hsCRP) evaluation adds prognostic information beyond that
available from the Framingham Risk Score. In contrast to several other
biomarkers that also reﬂect biological aspects of inﬂammation,
hypoﬁbrinolysis, and insulin resistance, hsCRP measurement is inex-
pensive, standardized, widely available, and has a decade-to-decade
variation similar to that of cholesterol [6].
Since there is now ample evidence linking both chronic inﬂamma-
tion and dyslipidemia not only in initiating but also promoting athero-
sclerotic injury; the goal of the JUPITER (Justiﬁcation for the Use of
Statins in Primary Prevention: An Intervention Trial Evaluating
Rosuvastatin) makes perfect sense. The JUPITER population has been
described as apparently healthy individuals with slight elevation in
their CRP levels and the study aimed to determine whether treatment
with rosuvastatin 20 mg/d would reduce the rate of ﬁrst major-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
2 A. López-Candales, D. Harris / IJC Metabolic & Endocrine 12 (2016) 1–2cardiovascular events [7]. At the time of study closure, it was found
that treatment with rosuvastatin signiﬁcantly reduced the primary
composite endpoint by 44% as compared with placebo. Most impor-
tantly, results of this trial clearly suggested that patients with elevat-
ed CRP stand to beneﬁt from statin therapy, regardless of their LDL-C
level [7].
It is quite evident that signiﬁcant advances have occurred in our
understanding of cardiovascular diseases. Nonetheless, additional
breakthroughs will undoubtedly occur as we gather more data
regarding alterations in inﬂammatory markers and how these
changes cause vascular injury and accelerated atherosclerosis.
Though considerable controversy still exists in how to diagnose indi-
viduals at a higher risk of developing cardiovascular disease at least
based on the last publication by the American College of Cardiolo-
gy/American Heart Association task force on practice guidelines it
was recommended that hs-CRP might be used to inform treatment
decision making if after quantitative risk assessment a treatment de-
cision remains uncertain [8].
Therefore, we certainly await with great enthusiasm the results of
the ongoing trials such as the CANTOS (Interleukin-1β inhibition
using cankinumab) and CIRT (low-dose methotrexate) trials.
In each of these trials an event driven protocol is using anti-
inﬂammatory measures in an attempt to reduce cardiovascular
events among stable coronary disease patients who remain at risk
of another events due to a persistent pro-inﬂammatory response
[9]. Finally, the COLCOT trial is currently evaluating if long-term
use of colchicine reduces cardiovascular events in patients post myo-
cardial infarction. The better-powered COLCOT trial is trying to rep-
licate ﬁndings of a previous smaller study were colchicine when
used with other standard secondary prevention interventions such
as statins was effective in preventing cardiovascular events in pa-
tients with stable coronary artery disease [10].
Since new experimental data continue to unravel new molecular
and cellular pathways of inﬂammation and how they are involved in
thepathogenesis of atherosclerosis, such as the IL-6 pathway; continued
vigilance on our part is required to follow the results of ongoing trials.
These not only would allow us to determine which markers are indeed
critical in identifying individuals at a higher risk of cardiovascular dis-
ease; but also which therapies might most useful in improving cardio-
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